ORGANOGENESIS HOLDINGS INC. Proceeds from (Repayments of) Secured Debt
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Proceeds from (Repayments of) Secured Debt of -$60.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfSecuredDebt · last filed 2024-02-29
- ORGANOGENESIS HOLDINGS INC. proceeds from (repayments of) secured debt for the quarter ending 2021-12-31 was $0.00.
- ORGANOGENESIS HOLDINGS INC. proceeds from (repayments of) secured debt for the quarter ending 2020-12-31 was $0.00.
- ORGANOGENESIS HOLDINGS INC. proceeds from (repayments of) secured debt for fiscal 2021 was -$60.00M, a 700.00% decline from fiscal 2020.
- ORGANOGENESIS HOLDINGS INC. proceeds from (repayments of) secured debt for fiscal 2020 was $10.00M, a 79.62% decline from fiscal 2019.
- ORGANOGENESIS HOLDINGS INC. proceeds from (repayments of) secured debt for fiscal 2019 was $49.08M.
| Period end | Proceeds from (Repayments of) Secured Debt 3 month | Proceeds from (Repayments of) Secured Debt 9 month | Proceeds from (Repayments of) Secured Debt 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$60.00M 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$60.00M 10-Q · filed 2021-11-09 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $10.00M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $10.00M 10-Q · filed 2021-11-09 | ||
| 2019-12-31 | $49.08M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |